Physician profile
Humera Khan
NPI 1821280256
$1,046.64
in general payments reported to CMS, 2019-2025
9 companies · $53.20 in 2025
The $53.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $322 · 2024: $671 · 2025: $53.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.79 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $231.57 | 2023-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $175.33 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Ardelyx, INC. | $136.36 | 2024 | Ibsrela |
| Sumitomo Pharma America, INC. | $82.01 | 2023-2024 | Gemtesa |
| Mannkind Corporation | $39.32 | 2023 | Afrezza |
| Csl Behring | $33.00 | 2025 | Hizentra |
| Glaxosmithkline, LLC. | $28.02 | 2023 | Arexvy, Shingrix |
| Theracosbio, LLC | $12.24 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humera Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.